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Abstract 22 
Background: Deletions in the C-terminus of the proto-oncogene c-Src kinase that are found in 23 
the viral oncogene v-Src and some advanced human colon cancers have been associated with 24 
increased kinase activity and elevated cellular invasion. Here, we used the human breast 25 
epithelial cell line MCF-10A to analyze the gene expression signature of a constitutively active C-26 
terminal mutant of c-Src, c-Src(mt), in comparison to the wildtype protein, c-Src(wt), which we 27 
characterized previously for its migration properties.  28 
Results: Genome-wide transcriptome analysis revealed that c-Src(mt) deregulated the 29 
expression levels of about 430 genes that are mainly involved in the cellular processes of 30 
migration and adhesion, apoptosis and protein synthesis. More than 80% of these genes have 31 
previously been linked to cellular migration, while the others play roles, for instance, in RNA 32 
transport and splicing processes. Consistent with the transcriptome data, c-Src(mt)-, but not c-33 
Src(wt)-expressing cells were able to migrate from blood vessels into lung tissue in a mouse 34 
model of tissue invasion in vivo. The gene expression profile of c-Src(mt)-expressing cells shows 35 
significant overlap with that of different primary human tumor samples, perhaps reflecting 36 
elevated Src activity in some cancerous cells.  37 
Conclusions: Expression of c-Src(mt) lead to elevated migratory potential. We used this model 38 
system to analyze the transcriptional changes associated with an invasive cellular phenotype. 39 
The herein identified genes and pathways deregulated by c-Src(mt) might be exploited as 40 
biomarkers or therapeutic targets for metastatic cells. 41 
Keywords: Src, Proto-oncogene, Migration, Invasion, Transcriptome  42 
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Background 43 
The c-Src proto-oncogene is the cellular homolog of the viral oncogene v-Src of the Rous 44 
Sarcoma Virus (RSV). c-Src is a non-receptor tyrosine kinase involved in a wide range of cellular 45 
functions including migration, invasion and adhesion. Elevated Src activity promotes oncogenic 46 
transformation [1]. The in vitro transforming capacity of activated Src kinase has originally been 47 
shown in RSV-infected and thereby v-Src-expressing chicken cells [2]. Src kinase-induced 48 
transformation can also occur in mammalian cells. This has been shown, for instance, by ectopic 49 
expression of v-Src in mouse fibroblasts [3]. In vitro studies with the human non-transformed 50 
epithelial breast cell line MCF-10A [4] have shown that the activation of Src kinase activity leads 51 
to transformation in vitro and tumor formation in nude mice [5-7]. Despite its known role in 52 
promoting cellular transformation, many of the functions of Src on the molecular level remain 53 
unclear [1].  54 
Known targets of Src kinase include focal adhesion proteins, adaptor proteins, cell cycle 55 
regulators and transcription factors. Src family kinases (SFKs) have been shown to modulate 56 
cell-cell and cell-matrix interactions and to promote the expression of matrix-degrading 57 
enzymes. The c-Src protein is regulated by reversible phosphorylation of tyrosine residues Y416 58 
and Y527 (numbering according to v-Src) and by protein-protein interactions through its Src 59 
homology 2 (SH2) and SH3 domains [1]. Phosphorylation of Y527 inactivates the kinase activity of 60 
c-Src by inducing a compact repressed protein conformation, while its dephosphorylation leads 61 
to an open, active conformation [8,9]. Y527 is phosphorylated by non-receptor tyrosine kinases, 62 
the C-terminal Src kinase (CSK) and the CSK-homologous kinase (CHK) [10]. Dephosphorylation 63 
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of Y527 is catalyzed by several protein tyrosine phosphatases (PTPs) such as PTPα [11], SH2 64 
domain-containing phosphatase-1 (SHP-1) [12] and SHP-2 [13]. Y416 is an autophosphorylation 65 
site whose phosphorylation is required for optimal c-Src kinase activity [14]. Moreover, various 66 
c-Src-interacting proteins can modulate its kinase activity non-enzymatically, including, for 67 
instance, focal adhesion kinase (FAK) [15] and SHP-2 [16] that bind to the SH2 and SH3 domains, 68 
respectively, leading to increased kinase activity.  69 
A conserved C-terminal hydrophobic motif, GENL, is shared by a number of ubiquitously 70 
expressed SFKs, including Src, Yes and Fyn. In contrast, SFKs lacking this motif, Lyn, Lck, Hck and 71 
Blk, are mainly expressed in non-adherent hematopoietic cells [17]. We noticed that the C-72 
terminus of c-Src was relevant for adherence and that its absence, for instance in the v-Src 73 
protein, seemed to contribute to non-adherence of cells. Therefore we suspected a possible 74 
role of the absent C-terminus in migration and invasion. The C-terminal GENL motif of c-Src has 75 
been described as binding motif for PDZ (postsynaptic density-95/discs large/zona occludens-1) 76 
domains, whereby the very C-terminal hydrophobic Leucine is crucial for this interaction. By 77 
substitution of this single amino acid from Leucine to Alanine, herein referred to c-Src(mt), we 78 
have recently demonstrated the loss of binding to PDZ domain-containing tumor suppressor 79 
proteins in MCF-10A and other cell lines. The c-Src-interacting PDZ proteins were the AF-6 (ALL-80 
1 fused gene from chromosome 6), the membrane protein, palmitoylated 2, MPP2, a protein 81 
related to the Drosophila tumor suppressor discs large-A, dlg-A, and LNX1 (Ligand-of-Numb 82 
protein X1) [17-20]. Disruption of these interactions via alteration of the C-terminal motif leads 83 
to constitutive activation of the c-Src protein and elevated kinase activity compared to the 84 
wildtype c-Src protein with the intact GENL sequence [17-20]. We have previously noticed that 85 
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the expression of c-Src(mt) and, to a lesser extent, of c-Src(wt) changes the cellular morphology. 86 
This includes impaired cell polarization and disorganization of the cytoskeleton in MCF-10A cells 87 
associated with increased cellular transformation, which has been characterized by several in 88 
vitro assays [17,19].  The ectopic expression of c-Src(mt) in MCF-10A cells leads to increased 89 
colony formation in soft agar and foci formation on normal cell culture plates as well as elevated 90 
invasion of matrigel [17]. Moreover, c-Src(mt)-expressing cells show disruption of spheroid cell 91 
growth into acinar cultures in extracellular matrix, impaired wound healing and elevated 92 
migration on basement membranes in vitro [19]. 93 
To investigate the underlying gene expression changes, we here subjected the identical cellular 94 
model we used previously, MCF-10A cells expressing either c-Src(mt) or the wildtype c-Src(wt) 95 
[17-20], to genome-wide transcription profiling. This cellular model allows for delineating the 96 
effects of the single point mutation within the c-Src protein by comparison of otherwise 97 
genetically identically cell lines. We show that c-Src(mt), but not c-Src(wt), significantly 98 
deregulated the expression levels of 434 genes, herein referred as c-Src(mt) effector genes. 99 
These genes were characterized by means of pathways and biological functions, allowing 100 
detailed insights into the gene expression program of c-Src(mt). The gene products are mainly 101 
involved in migration and adhesion, apoptosis and protein synthesis. Increased migratory 102 
potential of c-Src(mt)-expressing cells was suggested by the gene expression profile and 103 
corroborated in an in vivo mouse model of lung tissue invasion, in line with our previous in vitro 104 
findings [17-20]. Literature mining revealed that about 20% of the c-Src(mt) effector genes have 105 
previously not been associated with cellular migration. These genes are mainly involved in RNA 106 
transport and splicing processes. Comparison of the gene expression profile of c-Src(mt)-107 
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expressing cells with that of primary human cancer samples revealed significant overlap with 108 
about 60% of the tumor samples, indicating similarities between c-Src(mt)-expressing cells and 109 
some cancer cells that may have increased Src activity. 110 
 111 
Results 112 
Establishment of a c-Src(mt) cellular model 113 
To study the effects of c-Src(mt), we selected the human non-transformed MCF-10A cell line 114 
stably expressing c-Src(mt), or c-Src(wt) as control [17-19]. The c-Src(mt) protein is identical to 115 
c-Src(wt) except for a single L-to-A substitution within the C-terminal GENL sequence. This motif 116 
mediates binding to PDZ domain-containing tumor suppressor proteins and is shared by the 117 
ubiquitously expressed SFKs Src, Yes and Fyn, but not by Fgr, Hck, Lck, Lyn and Blk expressed in 118 
non-adherent hematopoietic cells (Figure 1A). The c-Src protein contains Src homology 1 (SH1) 119 
or kinase, SH2 and SH3 domains (Figure 1B). The experimental approach comprised the 120 
generation of stable cell lines, RNA isolation, Illumina RNA sequencing (RNA-Seq), mapping of 121 
generated reads to the human genome with Bowtie [21], the quantification of expression levels 122 
on the transcript level through RNA-Seq by Expectation Maximization (RSEM) [22], 123 
determination of significantly differentially expressed (DE) genes with DEseq [23] and their 124 
functional characterization.  125 
We stably transfected MCF-10A cells with either construct, c-Src(wt) or c-Src(mt), using lentiviral 126 
expression vectors (Additional file 1: Figure S1). Cells transfected with an otherwise identical 127 
expression vector but with a randomized nonsense sequence instead of c-Src were designated 128 
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mock cells. A tetracycline-inducible system allowed regulation of transgene expression by 129 
adding tetracycline (Tet) to the cell culture medium. Expression of the transgene in c-Src(wt)- 130 
and c-Src(mt)-transfected cells was verified by quantitative Reverse Transcriptase-PCR (qRT-131 
PCR) (primer sequences can be found in Additional file 1: Table S1) and Western Blot (Figure 132 
1C). RNA preparations displayed characteristic rRNA bands and no signs of degradation 133 
(Additional file 1: Figure S2). We selected those RNA preparations obtained from cells exposed 134 
to 1 µg/mL Tet for whole-genome expression profiling, as transgene expression was at 135 
physiological levels (Figure 1C). Of note, only c-Src(mt)-expressing cells exhibited a transformed 136 
phenotype upon exposure to Tet, including a stretched morphology, but no increased growth 137 
(data not shown). This is in accordance with our previous findings that expression of c-Src(mt) 138 
alters cellular morphology, but does not affect proliferation [19]. RNA preparations of all four 139 
cell lines were subjected to RNA-Seq, resulting in 99,100,544, 46,988,060, 38,071,856, and 140 
56,106,630 (naïve MCF-10A, mock, c-Src(wt) and c-Src(mt), respectively) quality control-passed 141 
reads. Reads were mapped to the human genome with Bowtie [21], which yielded 76,735,649 142 
(77.4%), 37,101,761 (79.0%), 30,474,883 (80.1%) and 43,473,640 (77.5%) mapped reads. Gene 143 
expression levels were then quantified on the transcript level with RSEM [22]. 144 
To learn about the global changes in gene expression induced through action of c-Src(wt) and c-145 
Src(mt), expression levels of both cell lines were compared to those of naïve MCF-10A cells, 146 
using DEseq [23]. The comparison mock vs. naïve MCF-10A served as negative control. Resulting 147 
logarithmic fold change values (logFC) of significantly DE genes (q ≤ 0.05) were plotted as 148 
density graphs (Figure 1D). While the profiles of mock and c-Src(wt) cells were almost identical 149 
and might reflect unspecific effects of the lentiviral transfection procedure, the profile of c-150 
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Src(mt)-expressing cells was different and showed more pronounced gene expression changes 151 
in both directions (down- and upregulated genes), but comparable q values (Additional file 1: 152 
Figure S3) and a higher proportion of upregulated genes (Figure 1D). The similar density graphs 153 
of mock- and c-Src(wt)-expressing cells gave a first indication that c-Src(wt) was insufficient to 154 
induce detectable Src-specific gene expression changes, as noted before [17-20,24].  155 
To verify Src activity, we performed qRT-PCR expression analysis of six known Src targets; p53 156 
(TP53) [25] and the related p63 (TP63), Cyclin D2 (CCND2) [26] and mir-205 (MIR205HG) [27], all 157 
of which suppressed by Src, as well as matrix metalloproteinase-2 (MMP2) [28] and hyaluronan 158 
synthase 2 (HAS2) [29] (Additional file 1: Figure S4). GAPDH served as control, which as 159 
expected showed identical expression levels in all four cell lines. While the reported effects of 160 
Src could be verified for all of these known Src target genes in the c-Src(mt)-expressing cells, 161 
cycle threshold (Ct) values in the c-Src(wt)-expressing cells were similar to those of the naïve 162 
MCF-10A and mock cells. This gave further credence to the notion that expression of c-Src(wt) 163 
alone was insufficient to induce deregulation of Src targets in our cellular model – in contrast, 164 
expression of c-Src(mt) did suffice to alter the expression levels of these genes. This is in 165 
accordance with previous findings that either activating mutations [17-20,24] or co-factors [1] 166 
are required for increased Src activity. This might well be because c-Src(wt) is maintained in an 167 
inactivated state through binding of PDZ domain-containing tumor suppressor proteins to its C-168 
terminal GENL sequence (Figure 1A). In contrast, c-Src(mt), due to mutation of this motif, has 169 
been shown to be impaired in binding to PDZ domains and is therefore constitutively active [19].  170 
We next sought to investigate effector genes regulated by c-Src(mt). To account for possible Src-171 
independent gene expression changes by the lentiviral transfection we selected the comparison 172 
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to mock cells instead of naïve MCF-10A cells as a more stringent control. This comparison, c-173 
Src(mt) vs. mock, yielded a total of 434 significantly (q ≤ 0.05) differentially expressed (DE) 174 
genes (Additional file 1: Table S2), herein referred to as c-Src(mt) effector genes, of which 52% 175 
(224 genes) were upregulated in the c-Src(mt)-expressing cells.  176 
All known c-Src(mt) target genes analyzed above by qRT-PCR also showed significant differential 177 
expression levels between c-Src(mt) and mock cells inferred by RNA-Seq except for TP53, likely 178 
because the corresponding expression levels were too similar (Additional file 1: Table S2 and 179 
Figure S4). Three genes mentioned above, TP63, CCND2 and MIR205HG, exhibited negative 180 
logarithmic fold change (logFC) values, whereas MMP2 and HAS2 showed positive logFC values 181 
with statistical significance, confirming our qRT-PCR results as well as previous findings [26-29]. 182 
Expectedly, GAPDH showed no altered expression. Interestingly, the expression level of 183 
endogenous c-Src was not altered, which was also seen in the Western Blot (Figure 1C). 184 
Therefore any effects on gene expression levels were due to activity of ectopically expressed c-185 
Src(mt) and not of endogenous c-Src, which was expressed at identical levels in all four cell lines. 186 
To further verify the RNA-Seq data, we selected eight additional genes with significant 187 
deregulation in the comparison c-Src(mt) vs. mock for qRT-PCR analysis (Additional file 1: Figure 188 
S5). logFC values were determined with the 2-ΔΔCT method and plotted against the logFC values 189 
obtained from RNA-Seq (Figure 1E). The strong correlation of R2=0.983 verified the expression 190 
levels inferred by RNA-Seq.  191 
In summary, the c-Src(mt)-expressing cells showed increased Src activity with previously 192 
reported effects on gene expression, and RNA-Seq data correlated well with qRT-PCR expression 193 
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analysis. The comparison c-Src(mt) vs. mock provided a comprehensive list of 434 c-Src(mt) 194 
effector genes for further characterization. 195 
 196 
c-Src(mt) deregulates genes involved in migration, apoptosis and protein synthesis 197 
To gain further insights into the gene expression program mediated by c-Src(mt), we subjected 198 
the set of c-Src(mt) effector genes to bioinformatic analyses. First, characteristics of gene 199 
products were assessed through Gene Ontology (GO) overrepresentation analysis (ORA) [30].  200 
Analysis of gene products falling into the GO category of ‘Biological Process’ (Figure 2A) showed 201 
that c-Src(mt) effector genes play a prominent role in organelle organization (GO:0006996, q = 202 
6.66 x 10-6) (Figure 2A), indicating changes in cellular morphology. This is in line with the notion 203 
that c-Src(mt) promotes an invasive phenotype in epithelial cells and impairs cell polarization 204 
and cytoskeletal organization [17-20]. Moreover, expression of c-Src(mt) significantly altered 205 
expression levels of genes involved in cellular responsiveness to cytokine stimulation 206 
(GO:0034097, q = 1.31 x 10-3). It has been noted that the composition of cytokines produced in 207 
tumor microenvironments play an important role in cellular migration [31]. For instance, c-208 
Src(mt)-expressing cells overexpress WNT5A (q = 9.28 x 10-3), a ligand of Frizzled receptors. 209 
Wnt/Frizzled signaling is known to be implicated in cellular migration [32]. Apoptosis-associated 210 
genes were deregulated in c-Src(mt)-expressing cells as well (GO:0006915, q = 1.31 x 10-3). 211 
Evasion of apoptosis is recognized as a hallmark of cancer, and Src is known to play a key role in 212 
this process [1]. Gene products of c-Src(mt) effector genes are mainly localized in the cytosol 213 
and nucleus (Figure 2A, ‘Cellular Component’), perhaps reflecting a predominant involvement in 214 
cytosolic signaling and gene regulation processes. An enrichment of proteins binding to 215 
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structural proteins such as actin (GO:0003779, q = 5.33 x 10-4) indicate that c-Src(mt) effector 216 
genes are implicated in cytoskeleton remodeling and migration (Figure 2A, ‘Molecular 217 
Function’).  218 
To further characterize the roles of c-Src(mt) effector genes, we performed pathway enrichment 219 
analysis using ConsensusPathDB [33]. We found that c-Src(mt) effector genes mainly affect 220 
pathways involved in cell migration and adhesion (Figure 2B, yellow), including hemidesmosome 221 
assembly and integrin pathways, as well as protein synthesis (Figure 2B, blue) and apoptosis 222 
(Figure 2B, red). 223 
c-Src(mt) effector genes involved in cellular migration and adhesion comprise integrin receptor 224 
components ITGA2, ITGA6 and ITGAV, all of which are downregulated (Figure 2C). Integrin 225 
receptors are known to attach cells to the extracellular matrix (ECM) by binding to ECM 226 
components such as laminin, collagen, fibronectin and E-cadherin, and their deregulation 227 
promotes invasiveness. For instance, ITGAV expression has been linked with metastatic activity 228 
in colorectal cancer [34], and ITGA2 genetic variants may be associated with invasion of gastric 229 
cancer [35]. On the other hand, a diversity of components of the ECM itself was deregulated by 230 
the action of c-Src(mt). This includes upregulation of Decorin (DCN), Fibronectin 1 (FN1), Fibrillin 231 
1 (FBN1), and downregulation of E-cadherin (CDH1) genes. Various genes encoding collagen 232 
chains are either up- (COL8A1, COL12A1, COL28A1) or downregulated (COL17A1). Of note, 233 
overexpression of Decorin [36], Fibronectin 1 [37] and collagen chains COL8A1 [38] and 234 
COL12A1 [39] have been recently shown to promote invasiveness of different cancer types. This 235 
indicates that c-Src(mt) significantly alters cell-matrix interactions, thereby decreasing cell 236 
adhesion and promoting cellular migration and invasiveness. Moreover, matrix 237 
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metalloproteinase-2 (MMP2), an enzyme degrading type IV collagen, the major constituent of 238 
basement membranes, is upregulated by c-Src(mt). Increased expression of MMP2 has been 239 
shown to correlate with cellular invasion [1]. Except for the collagen chain COL8A1 and 240 
Fibronectin 1, none of the above mentioned genes involved in cell adhesion are deregulated by 241 
c-Src(wt) (Figure 2C), further verifying that the activating mutation of c-Src(mt) promotes Src 242 
activity. 243 
c-Src(mt) effector genes involved in apoptosis signaling include those involved in maintaining 244 
cytoskeleton integrity such as Adducin 1 (ADD1) and Plectin (PLEC), both of which were 245 
upregulated by c-Src(mt) (Figure 2C). Adducins are components important for the cortical 246 
cytoskeleton network and are subject to Caspase-3-mediated cleavage during cisplatin-247 
mediated apoptosis [40]. Plectin serves a cross-linking molecule for the cytoplasmic filament 248 
system and is thus involved in maintaining cytoskeleton integrity, and its cleavage by Caspase-8 249 
occurs early during TNF receptor-mediated apoptosis [41]. Upregulation of cytoskeletal 250 
components such as Adducin 1 and Plectin by c-Src(mt) might thus interfere with caspase-251 
mediated cytoskeleton instability, thereby suppressing apoptosis. While ADD1 was not 252 
deregulated by c-Src(wt), PLEC was upregulated, however, less markedly compared with c-253 
Src(mt) (Figure 2C). 254 
While the involvement of Src in cell adhesion and apoptosis is well-known [1], we also found a 255 
surprisingly large number of pathways involved in translation and protein synthesis with an 256 
overrepresentation of c-Src(mt) effector genes (Figure 2B). These include various steps of 257 
protein synthesis, such as mRNA transport and degradation, translation initiation, as well as 258 
amino acid biosynthesis and transport (Additional file 3). A number of genes encoding 259 
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eukaryotic translation initiation factors (EIFs), including EIF3A, EIF3E, EIF4A2 and EIF4G1 and 260 
other proteins involved in translation initiation were upregulated by c-Src(mt) (Figure 2C). 261 
Genes for small and large subunit ribosomal proteins, RPL29, RPL31 and RPS24, were also 262 
upregulated. Amino acid transport across the cell membrane appeared to be heavily influenced 263 
by c-Src(mt) through deregulation of a number of genes encoding amino acid-transporting 264 
solute carrier proteins (SLCs), such as SLC1A5, SLC3A2, SLC7A2, SLC7A5 and SLC38A1. In 265 
addition, amino acid biosynthesis was regulated by c-Src(mt), including downregulation of genes 266 
for serine hydroxymethyltransferases 1 and 2 (SHMT1/2), enzymes that catalyze the conversion 267 
of serine to glycine, and downregulation of the glycine dehydrogenase (decarboxylating) gene 268 
(GLDC) whose gene product degrades glycine. We propose that c-Src(mt) stimulates global 269 
protein synthesis by increasing the number of ribosomes and the intracellular levels of 270 
translation initiation factors and free amino acids. Moreover, genes involved in mRNA decay, 271 
such as the CNOT6 cytoplasmic deadenylase, were downregulated by c-Src(mt), while the 272 
polyadenylate-binding protein 1 (PABPC1) gene, essential for translation initiation, was 273 
upregulated. Moreover, the overall higher proportion of upregulated compared to 274 
downregulated genes on the transcriptional level induced by the expression of c-Src(mt) 275 
indicated an elevated pool of available mRNAs, further increasing protein expression, including 276 
that of pro-invasion and anti-apoptosis genes (Figure 2A-C). Of note, only few of the above 277 
mentioned genes involved in protein synthesis were deregulated by c-Src(wt) (Figure 2C). We 278 
conclude that the activation of protein synthesis requires the constitutively active form of c-Src, 279 
c-Src(mt). 280 
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In summary, physiological expression of c-Src(mt) was sufficient to modulate cell 281 
migration/adhesion, apoptosis and protein synthesis mainly through deregulation of genes 282 
involved in integrin signaling, ECM remodeling, composition of the cytoskeleton and of the 283 
translation machinery.  284 
 285 
c-Src(mt) promotes tissue invasion in vivo 286 
Elevated Src activity frequently correlates with increased tissue invasion activity [42]. The 287 
change in expression levels of migration/adhesion-associated genes in the c-Src(mt)-expressing 288 
cells (Figure 2B-C) suggested that these cells might also bear increased invasive potential. To 289 
test whether c-Src(mt)-expressing cells exhibit increased tissue invasion in vivo, we employed an 290 
established mouse model of lung tissue invasion [43]. 8-weeks old SCID mice were intravenously 291 
injected with 9 x 105 naïve MCF-10A, c-Src(wt), c-Src(mt), or mock-expressing cells. To induce 292 
transgene expression in the engineered cell lines, 1 µg/mL Tet was added to the drinking water 293 
of all animals. Mice were sacrificed after 42 days, and lung tissues analyzed phenotypically 294 
(Figure 3A). Macroscopic analysis revealed visible lung metastases exclusively in those mice that 295 
have received c-Src(mt)-expressing cells, indicating that expression of c-Src(mt) predisposes 296 
tumor cells to extravasate and migrate into epithelial tissue. Lung metastases were found in two 297 
of five mice injected i.v. with c-Src(mt)-expressing cells, while they were absent in the lungs of 298 
mice that received c-Src(wt)-expressing cells (0/4) or mock and naïve MCF-10A cells (both 0/5) 299 
(Figure 3B). Representative histological H&E-stained sections are shown in Figure 3C. 300 
Subsequent histological analyses corroborated the presence of metastases in the macroscopic 301 
positive lungs of mice that have received c-Src(mt)-expressing cells (Figure 3D). 302 
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Immunohistological analyses indicated proliferating tumor cells mainly at the outer radial 303 
boarder of the lung metastases (Ki67 in Figure 3D), with little necrosis (Cleaved Caspase 3). Only 304 
a few F4/80+ macrophages, Ly6G+ granulocytes, CD3+ T cells as well as B220+ B cells were found 305 
at the boarder of the metastases, indicating the failure of the murine immune system to attack 306 
tissue-invading cells. 307 
The ability of c-Src(mt)-expressing cells to invade lung tissue in mice verified the expression 308 
signature that contained migration/adhesion-associated genes (Figure 2B-C) and is in 309 
accordance with previous findings that cells expressing this c-Src mutant exhibit increased 310 
motility in in vitro migration assays [19]. In contrast, we could not detect any tissue invasion in 311 
mice that received c-Src(wt)-expressing cells. This might well be due to the fact that most of the 312 
migration/adhesion-associated genes that were deregulated by c-Src(mt) were not altered by c-313 
Src(wt) (Figure 2C). This is in accordance with the fact that overexpression of the wildtype c-Src 314 
protein alone causes only minimal changes in the migratory activity [19,29,44], which may be 315 
explained by interactions with PDZ domain-containing tumor suppressors with the C-terminal 316 
GENL motif of the c-Src(wt) protein that suppress its kinase activity [17,18,20]. This is also 317 
corroborated by the observation that c-Src(mt)- but not c-Src(wt)-expressing cells exhibited a 318 
transformed phenotype upon stimulation with Tet in cell culture (data not shown). 319 
 320 
Non-migration-associated c-Src(mt) effector genes are involved in mRNA transport, 321 
translation and iron transport 322 
The role of activated c-Src in promoting metastasis is well-known [1]. However, our 323 
transcriptome data also revealed a prominent effect of c-Src(mt)-expression on protein 324 
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synthesis (Figure 2B). To identify c-Src(mt) effectors that are not associated with metastasis, we 325 
employed a literature mining approach in PubMed abstracts, using a defined lexicon of terms 326 
associated with migration. The majority of c-Src(mt) effector genes, 415 of 434 (95.6%) were 327 
found in PubMed abstracts. Of these, 344 (83%) were significantly linked to migration, which 328 
might reflect that previous studies investigating Src activity were biased towards its migration-329 
promoting activity. On the other hand, 71 genes (17%) were not linked to migration (highlighted 330 
green in Additional file 1: Table S2). These 71 genes are of particular interest as they might 331 
contain genes that have previously not been associated with Src activity. To get an idea about 332 
the cellular processes these 71 genes are implicated in, they were subjected to GO 333 
overrepresentation analysis. Interestingly, these genes appeared to be mainly involved in 334 
(m)RNA transport and splicing (Figure 4). This corroborates our finding that c-Src(mt) exerts a 335 
previously underestimated role in the regulation of gene expression at the level of translation 336 
(Figure 2B-C). Our data so far suggests that the constitutively active c-Src(mt) mutant, in 337 
addition to promoting metastasis, may have an impact on protein synthesis. This function, to 338 
our knowledge, has not yet been attributed to Src activity. 339 
 340 
c-Src(mt)-expressing cells exhibit characteristics of primary human tumors and progression to 341 
metastasis 342 
Increased Src activity is a frequent feature of different human cancers [1]. Therefore, we 343 
wondered whether c-Src(mt)-expressing cells show similarities with primary human cancer cells. 344 
To address if c-Src(mt)-expressing cells share similar gene expression profiles with primary 345 
human cancers, we used the ONCOMINE cancer microarray database [45] for comparison with 346 
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c-Src(mt) effector genes. The gene sets in ONCOMINE consists of genes that were found 347 
differentially expressed when comparing either tumor vs. normal tissue or metastatic vs. 348 
primary tumors and are provided as gene sets within the database. 38 of 70 (54%) of the 349 
ONCOMINE gene sets of normal tissue vs. cancer pairs showed significant (q ≤ 0.05) overlap 350 
(Figure 5A, left). Of note, this included most of the breast cancer (4/6), leukemia (5/6), ovarian 351 
(5/7), prostate (7/13) and renal cancers (3/5), as well as all liver cancer samples (4/4). Increased 352 
Src activity has been identified in breast, ovarian, liver cancer and leukemia [42], as well as 353 
prostate [46] and renal cancer [47]. Analysis of ONCOMINE datasets of cancer progression 354 
(metastatic vs. localized, n=42) revealed that 18 of 42 (40%) of these gene sets had significant 355 
overlap with c-Src(mt) effector genes (Figure 5A, right), including most of the lung (4/5) and the 356 
prostate (9/16) cancer samples. Increased Src activity has been shown to be associated with 357 
increased metastasis, amongst others, in lung [42] and prostate cancer [48]. Therefore, c-358 
Src(mt)-expressing cells proved to be a valid, albeit simplified, model for some human cancers 359 
and their progression to metastasis. This suggests that the single amino acid mutation of c-360 
Src(mt) can indeed induce a ‘cancer-like’ state of the cell, in the sense that it affects similar 361 
genes found to be dysregulated in diverse tumor or metastatic cells. 362 
We next sought to investigate whether the non-migration-associated c-Src(mt) effector genes 363 
(Additional file 1: Table S2) in particular are relevant for human cancer. Therefore, we searched 364 
the ONCOMINE database for any evidence of their deregulation in normal tissue vs. cancer 365 
pairs. We identified 18 genes that showed either significant (q ≤ 0.05) up- (eight genes) or 366 
downregulation (ten genes) in at least 50% of the respective cancer types (Figure 5B) similar to 367 
our cellular model, in which mock cells represent normal tissue and c-Src(mt)-expressing cells 368 
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correspond to cancer cells. Of note, most of these genes were deregulated in leukemia samples. 369 
Thus, the non-migration-associated c-Src(mt) effector genes are likely most relevant for this 370 
cancer type. This might reflect the fact that the absence of the PDZ binding motif at the C-371 
terminus of c-Src(mt) is reminiscent of other SFK members, such as Fgr or Hck (Figure 1A) 372 
expressed in non-adherent cells of the hematopoietic system.  373 
 374 
Discussion 375 
Here we have analyzed a cellular model of C-terminally mutant and constitutively active c-376 
Src(mt) by its expression at physiological levels in non-transformed human cells. Of note, the 377 
expression of c-Src(mt), but not of c-Src(wt) at comparable levels (Figure 1C), altered the 378 
expression of previously reported Src targets (Additional file 1: Figure S4). This is in accordance 379 
with previous findings that activation of c-Src, either by activating mutations or deletions in the 380 
C-terminus [17-20,24], or via the action of co-factors, such as FAK [1], is required for its 381 
transforming activity. Whole-genome transcriptome analysis revealed that most of the 434 382 
genes deregulated by c-Src(mt) are implicated in migration and adhesion, apoptosis and protein 383 
synthesis (Figure 2A-C). In accordance with transcriptome data and previous findings, c-Src(mt)-384 
expressing cells exhibited increased invasion of lung tissue and metastasis formation in vivo 385 
after i.v. injection in mice (Figure 3A-D). In contrast, c-Src(wt)-expressing cells did not induce 386 
metastases in this animal model, reflecting that expression levels of most genes relevant for 387 
migration/adhesion that were deregulated by c-Src(mt) were not altered by c-Src(wt). The 388 
herein investigated c-Src proteins, c-Src(wt) and c-Src(mt), only differ by a single amino acid at 389 
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the very C-terminus (Figure 1A). The C-terminal GENL sequence of c-Src is a known binding 390 
motif for PDZ domain-containing tumor suppressor proteins [17-20]. Binding of these tumor 391 
suppressors keeps c-Src in an inactivated state, which may explain why expression of c-Src(wt) 392 
with the intact GENL motif, in contrast to c-Src(mt) with the C-terminal GENA sequence, was 393 
insufficient to alter the expression of known Src targets (Additional file 1: Figure S4) or to induce 394 
metastatic behavior (Figure 3A-D). The in vivo data shown here is in agreement with previous 395 
findings showing that c-Src(mt)-expressing cells exhibits increased migration activity compared 396 
to c-Src(wt)-expressing cells in vitro [17-20]. 397 
Literature mining revealed that more than 80% of c-Src(mt) effector genes have previously been 398 
linked to cellular migration. The remaining 17% of genes showed an enrichment genes involved 399 
in (m)RNA transport and splicing processes (Figure 4), which are relevant for gene expression at 400 
the level of translation. Interestingly, various cellular pathways relevant for protein synthesis 401 
showed an enrichment of genes deregulated by c-Src(mt) (Figure 2B). To our knowledge, the 402 
deregulation of protein synthesis has not yet been linked with Src activity, perhaps because 403 
most previous studies were mainly focused on investigating its metastasis-promoting potential. 404 
Therefore, we suggest that Src activity is associated with an increase in global protein synthesis. 405 
Interestingly, this function has recently been attributed to another proto-oncogene, c-Myc [49]. 406 
The importance of protein synthesis in cancer development has been neglected historically [49]. 407 
However, recent evidence underlines the importance of deregulated translation in different 408 
cellular processes, including cancer progression. Using ribosomal profiling, Hsieh et al. [50] have 409 
shown that oncogenic signaling of the mammalian target of rapamycin (mTOR) kinase heavily 410 
influences the translational machinery, and thereby cancer invasion and metastasis, through 411 
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increased translation of pro-invasion mRNAs. Consequently, components of the translational 412 
machinery, such as the translation initiation factor EIF4E, are now being explored as therapeutic 413 
targets to treat cancer [49]. In line with these findings, we found evidence that Src activity 414 
causes the deregulation of different steps of the translational control. Proteins that are 415 
upregulated by c-Src(mt) include those acting as translation initiation factors, ribosomal 416 
proteins and those promoting mRNA stability, thereby potentially promoting the ‘cancerous’ 417 
translation machinery. Interestingly, Src is known to activate phosphoinositide 3-kinase (PI3K) 418 
by phosphorylation, whose downstream targets include mTOR [49]. mTOR stimulates protein 419 
synthesis by phosphorylating EIF4EBP1 and ribosomal S6 kinase p70S6K1/2. Consequently, 420 
mTOR and downstream targets p70S6K1/2, EIF4EBP1 and ribosomal protein 6 are 421 
phosphorylated/activated by Src [49]. We therefore propose a dual mechanism of translational 422 
activation by Src, through cytosolic activation of the mTOR pathway and transcriptional 423 
activation of components of the translational machinery, as shown in this study. This may lead 424 
to increased translation of pro-invasive and anti-apoptotic mRNAs, thus potentially promoting 425 
cellular migration. 426 
Another potential target for cancer therapies is FAK, a cytoplasmic tyrosine kinase that is a key 427 
downstream signal transducer of integrin receptors [51,52]. FAK is directly phosphorylated by 428 
Src kinase, leading to the activation of multiple intracellular signaling pathways that are 429 
relevant, amongst others, for apoptosis and cell migration [52]. FAK and Src kinase synergize in 430 
cell migration and invasion [53,54]. We have recently shown that the expression of c-Src(mt) 431 
leads to increased levels of phosphorylated FAK in MCF-10A cells concomitant with elevated cell 432 
motility [19]. The transcriptome analysis of this study revealed that the mRNA expression level 433 
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of FAK was not significantly influenced by c-Src(mt), as FAK (gene symbol: PTK2 for Protein 434 
Tyrosine Kinase 2) was not among the c-Src effector genes (Additional file 1: Table S2). Together 435 
with our previous findings [19] the results here indicate that FAK activation by c-Src(mt) mainly 436 
involves its Src-dependent phosphorylation while transcription levels remain unaltered. Of note, 437 
both upregulation and increased phosphorylation of FAK have been detected in numerous 438 
human metastatic tumors compared to benign, non-metastatic tumors or normal tissues [52]. 439 
For instance, increased FAK phosphorylation has been identified in primary breast cancer 440 
specimens and breast cancer cell lines compared to normal tissue [55,56]. 441 
In line with these findings, the gene expression changes induced by c-Src(mt) showed significant 442 
similarities with expression profiles of many primary human cancers, especially breast cancer, 443 
leukemia, ovarian, prostate and renal cancers (Figure 5A). Of note, we detected significant 444 
overlap with expression profiles of some colon cancers (3/6 tumor vs. normal tissue and 1/3 445 
metastatic vs. localized), for which activating C-terminal mutations of the c-Src gene have been 446 
reported before [24]. Thus, c-Src(mt)-expressing cells not only exerted increased migratory 447 
potential, but also showed similarities to the gene expression signature of some primary cancer 448 
disease, which may become metastatic later. It has to be noted that tumorigenesis and 449 
progression to metastasis in vivo is a multi-step process that involves the inactivation of tumor 450 
suppressor genes and the acquisition of oncogenic mutations [57,58]. This study aimed to 451 
characterize the function and effectors of activated Src kinase with loss of binding to PDZ 452 
domains and not mechanisms of cancer formation or metastasis in general. 453 
Previous genome-wide analyses of the effect of Src activity on gene transcription include 454 
microarray analyses of v-Src-transformed mouse cells [3,59] or RSV-transformed chicken cells 455 
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[60,61]. One study analyzed the gene transcription profile of MCF-10A cells transformed with 456 
ER-Src, a derivative of v-Src that is fused to the ligand-binding domain of the estrogen receptor 457 
[7]. In contrast, the cellular model described herein reduces the metastatic mechanism to a 458 
single point mutation in the c-Src protein and potential escape from tumor suppressors, leading 459 
to increased kinase activity. This might explain why there is only little concordance with the c-460 
Src(mt) effector genes identified in this study and the v-Src-regulated genes identified by others 461 
[3,7,59-61]. Other more complicated multi-component mechanisms certainly exist but may be 462 
difficult to analyze.  463 
In addition, we identified 71 c-Src(mt) effector genes that have not been previously associated 464 
with metastasis, which were mainly involved in the processes of RNA transport and splicing, and 465 
thus influence protein synthesis (Figure 4). A number of these genes showed deregulation in 466 
human primary cancer samples as well, especially in leukemia (Figure 5B). SFK members lacking 467 
the ability to bind to PDZ proteins, such as Fgr or Hck, are typical for non-adherent 468 
hematopoietic cells. Thus, non-adherent hematopoietic cells resemble metastatic alterations of 469 
adherent cells to some degree. 470 
 471 
Conclusions 472 
This study first defines the regulatory landscape of a specific C-terminally mutated form of the c-473 
Src kinase, c-Src(mt). Cells expressing this mutant extravasated and migrated into lung tissue of 474 
mice in vivo, thus mimicking metastasizing cells. Among known genes, we describe a number of 475 
genes not yet associated with this behavior. They might deserve further investigation as 476 
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putative biomarkers of invasive cells or therapeutic approaches especially in the context of Src-477 
driven progression to metastasis. 478 
 479 
Methods 480 
Cells 481 
MCF-10A cells (ATCC-CRL-10317) were obtained from the American Type Culture Collection and 482 
grown in complete growth medium [DMEM/F12 (Gibco) with 2 mM L-glutamine supplemented 483 
with 20 ng/mL epidermal growth factor (Sigma), 100 ng/mL cholera toxin (Sigma), 10 ng/mL 484 
insulin (Sigma), 500 ng/mL hydrocortisone (Sigma) and 5% horse serum (Gibco)]. Cells were 485 
maintained at 37°C with 5% CO2. 486 
Lentiviral constructs 487 
The HA-tagged Src constructs are described elsewhere [17-19]. Lentiviral particles for TetR-488 
inducible expression of c-Src(wt) (LVP-Src-wt) and c-Src(mt) (LVP-Src-mt), as well as a short 489 
nonsense construct (LVP-mock) conferred resistance to Blasticidin S. LVP017-Neo allows 490 
constitutive expression of TetR and confers resistance to G418 (Additional file 1: Figure S1). 491 
Lentiviral particles were prepared by AMS Biotechnology (United Kingdom). Sequences were 492 
confirmed by capillary sequencing. 493 
Generation of stably expressing cells 494 
MCF-10A cells were grown to 50% confluence in complete growth medium. Cells were 495 
incubated with LVP017-Neo at a multiplicity of infection (MOI) of ten and lentiviral expression 496 
particles (MOI = 3) for 72h. Then, medium was replaced with fresh complete growth medium 497 
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containing 60 µg/mL G418 (Gibco) and 3.5 µg/mL Blasticidin S (Invitrogen) for 14 days to select 498 
double-positive cells. Untransfected control cells were killed within 14 days when exposed to 499 
either 60 µg/mL G418 or 3.5 µg/mL Bsd. Double-positive cells were maintained in complete 500 
growth medium with 30 µg/mL G418 and 1.75 µg/mL Bsd. Expression of TetR mRNA was 501 
confirmed by qRT-PCR and was at comparable levels in the three engineered cell lines. The 502 
tetracycline-inducible system allowed regulation of transgene expression by adding tetracycline 503 
(Tet) to the cell culture medium. Inducible expression of the transgene in c-Src(wt)- and c-504 
Src(mt)-transfected cells was verified by qRT-PCR and Western Blot. For the subsequent gene 505 
expression analyses we selected cell populations that showed similar levels of c-Src(wt) and c-506 
Src(mt) expression at physiological levels (Figure 1C). 507 
Preparation of total RNA 508 
Cells were grown to ~70% confluence in complete medium supplemented with 30 µg/mL G418 509 
and 1.75 µg/mL Bsd. Tetracycline (Sigma-Aldrich) was added to the culture medium and cells 510 
were incubated for 24h. Then, total RNA was extracted with Trizol (Invitrogen) according to the 511 
manufacturer’s recommendations. The RNA was precipitated at -80°C and pelleted by 512 
centrifugation at 12,000 x g for 10 minutes. The pellets were washed with 75% ethanol, air-513 
dried and solubilized in nuclease-free water. Remaining DNA was removed with the RNase-free 514 
DNase set from Qiagen according to the manufacturer’s protocol. Then, the solution was 515 
subjected to phenol-chloroform extraction. RNA integrity was assessed by agarose gel 516 
electrophoresis.  517 
Primer design and synthesis 518 
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Primers for quantitative Real-Time PCR (qRT-PCR) were designed such that PCR products were 519 
smaller than 300 bp and intron-spanning, using the primer3 program 520 
(http://primer3.wi.mit.edu) [62] and cDNA sequences retrieved from the UCSC Genome 521 
Browser and the current release of the human genome [63]. The GAPDH primer pair has been 522 
described previously [64]. The forward primer for mu SRC_HA is situated within the HA tag of c-523 
Src constructs, c-Src(wt) and c-Src(mt), to avoid amplification of endogenous c-Src expressed by 524 
MCF-10A cells. Primers were synthesized by Metabion (Martinsried, Germany). For a complete 525 
list of primer sequences used in this study refer to Additional file 1: Table S1. 526 
Quantitative real-time PCR 527 
Total RNA preparations were reverse-transcribed with the High Capacity cDNA Reverse 528 
Transcription Kit (Applied Biosciences) according to the manufacturer’s recommendations. RT-529 
products were quantified with the Fast SYBR Green Master Mix (Applied Biosystems) on an 530 
Applied Biosystems 7900HT Fast Real-Time PCR System. Cycle conditions were: 10 min. 531 
incubation at 95°C, followed by 50 amplification cycles of 95°C for 15 s and 58°C for 1 min. 532 
Western Blots 533 
Cells were resuspended in buffer A (10 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM 534 
DTT, protease inhibitor cocktail) and layzed mechanically. After centrifugation for 5 min at 2500 535 
x g the pellet then was subjected to DNase I digestion (10 mM HEPES, pH 7.4, 10 mM NaCl, 3 536 
mM MgCl2, 0.2U DNase I, 1 mM DTT, protease inhibitor cocktail) and centrifuged again as 537 
described before. The resulting supernatant was combined with the first one and the total 538 
protein concentration determined using the Bradford method (Sigma-Aldrich) following the 539 
manufacturer’s instructions. 30 µg of lysate were subjected to SDS-polyacrylamide gel 540 
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electrophoresis (PAGE) and immunoblotting. Primary antibodies used in the experiment were: 541 
anti-Src clone GD11 (Millipore), and anti-GAPDH (Ambion #AM4300). The secondary antibody 542 
was Peroxidase-AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch). 543 
RNA sequencing 544 
1 μg of total RNA preparations of the four cell lines were subjected to cDNA library preparation 545 
with the NEBNext Ultra RNA Library Prep Kit (New England Biolabs) and subsequently to DNA 546 
sequencing on an Illumina Genome Analyzer IIx sequencer with a 100 bp paired-end multiplex 547 
run, yielding 99,100,500 (naïve MCF-10A), 46,988,060 (mock), 38,071,856 (c-Src(wt)) and 548 
56,106,530 (c-Src(mt)) quality control-passed reads. 549 
Sequence read alignment 550 
The Illumina paired-end sequence reads were mapped to the UCSC hg19 human reference 551 
genome using the Bowtie read aligner (0.12.8 release, default parameters) [21]. 552 
Gene expression and determination of differential expression 553 
Via the Illumina RNAseq technology, gene expression in four different cell lines was measured:  554 
(1) non-transfected cells (naïve MCF-10A) 555 
(2) cells transfected with the mock lentiviral vector  556 
(3) cells transfected with the c-Src(wt) lentiviral vector  557 
(4) cells transfected with the c-Src(mt) lentiviral vector 558 
RNA expression levels were determined with a standardized analysis pipeline based on RSEM 559 
(RNA-Seq by Expectation Maximization) [22]. DESeq [23] was then used to determine 560 
differential expression of genes comparing different cell lines. Genes with an FDR-adjusted q 561 
value ≤ 0.05 in their fold change were considered as differentially expressed.  562 
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Gene Ontology overrepresentation 563 
The ConsensusPathDB [33] was used to identify predominantly occurring GO terms among the 564 
candidate genes in order to determine functional commonalities between them. p values were 565 
derived from a Fischer’s exact test performed for the candidate genes against the background 566 
set of all genes in the human genome. Correction for multiple testing was done using the FDR 567 
(false discovery rate) method that resulted in q values.  568 
Pathway overrepresentation 569 
Overrepresented pathways involving the candidate genes were accumulated via the interface of 570 
the ConsensusPathDB (Release 25) [33], a pathway database that integrates interaction data 571 
from currently 31 public resources. p and q values were calculated analogously to the above GO 572 
analysis. 573 
Mouse experiments 574 
All animal procedures were done in accordance with the regulations of the Cantonal Veterinary 575 
Authority of Zurich and the Swiss laws on animal protection. For the tumor growth studies, 576 
severe combined immune-deficient (SCID) mice were obtained from Charles River laboratories. 577 
Eight-week-old female mice were intravenously injected with 9x105 MCF-10A cells or c-Src(wt), 578 
c-Src(mt) or mock cells. Lung tissues were evaluated after 42 days. 1 µg/mL of Tet was added to 579 
the drinking water of all mice to induce transgene expression in engineered cell lines. 580 
Immunohistochemistry 581 
Lung tissues were fixed with 4% paraformaldehyde and embedded in paraffin. Paraffin sections 582 
(2 μm) were either stained with haematoxylin / eosin (H&E) or automated 583 
immunohistochemistry staining with rabbit-anti-CD3 for T cells, rat-anti-B220 for B cells (both 584 
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BD Biosciences), rat-anti-F4/80 for macrophages (BMA Biomedicals AG), rat-anti-Ly6G for 585 
granulocytes (BD Pharmingen), rabbit-anti-Ki67 for proliferating cells (Neomarkers), rabbit-anti-586 
cleaved caspase 3 for apoptotic cells (Cell Signaling, Danvers, USA), rabbit-anti-rat HRP and anti-587 
rabbit-poly HRP (Leica Bond Polymer Refine Detection DS9800). Image acquisition was 588 
performed on DotSlide BX51 (Olympus), SCN400 (Leica), Axio Z1 (Zeiss) or BX53 (Olympus) 589 
microscopes. 590 
Literature mining 591 
We aimed to find genes that can be associated to cellular migration characteristics but have so 592 
far not been dealt with in that context. Thus, we used an automated literature mining approach 593 
to scan PubMed abstracts for information on the candidate genes with respect to migration. For 594 
that purpose we defined a lexicon of migration-related terms (migration, metastasis, 595 
pseudopodia, wound healing, adherence, adhesion, homing, pathfinding, motility, angiogenesis, 596 
invasion, cancer progression, PDZ domain, cytoskeleton) and searched for the genes' co-597 
occurrence with those terms. We used an evidence score defined as 598 
 599 
      sij = log2( Pij / (Pi Pj) ) 600 
 601 
to quantify literature evidence for a gene. 602 
Here, Pij is the frequency of co-occurrence of the lexicon term j and the gene j and Pi and Pj are 603 
their marginal frequencies. The evidence score for each gene was computed as the sum of co-604 
associations over the entire lexicon  605 
 606 
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     sj = Σi sij . 607 
 608 
A high score indicates that a gene has often been related to metastasis and other terms of the 609 
lexicon. It is thus of particular interest to further analyze those genes that have a low or 610 
negative evidence score. 71 genes showed no evidence. 611 
Cancer gene expression profiles 612 
Gene set enrichment analysis was performed on the basis of publicly available cancer gene 613 
expression datasets from the ONCOMINE database [45]. We looked for cancer datasets that 614 
showed similar expression profiles to our c-Src(mt)-expressing cells vs. mock cells. Focus was 615 
laid on studies that compared different stages of cancer tissue, i.e. sets marked with NP for 616 
‘normal tissue vs. cancer’ and CP for ‘cancer progression vs. primary tumor’. At the state of 617 
writing there were 112 of such data sets to be found, all of which were considered. Ideally, 618 
those sets containing data for normal cancer tissue as well as metastatic tissue show a 619 
significant overlap of differentially expressed genes when compared to our set of c-Src(mt) 620 
effector genes. To calculate the significance of overlap of our effector genes with the gene sets 621 
from the ONCOMINE data sets, we performed Fischer’s exact test and corrected for multiple 622 
testing using the FDR method.  623 
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 825 
Figure Legends 826 
Figure 1 Establishment of a cellular model of activated c-Src. (A) Alignment of C-terminal 827 
moieties of human Src family kinases (SFKs). A conserved binding motif for PDZ domain-828 
containing tumor suppressor proteins is shown green. (B) Domain organization of c-Src 829 
constructs used in this study. (C) Detection of transgene expression in engineered MCF-10A cells 830 
by Western Blot (upper part) and qRT-PCR (lower part). The α-Src antibody binds to both human 831 
(hu) and murine (mu) c-Src proteins. The mu c-Src constructs (61.3 kD) are bigger than the 832 
endogenous hu c-Src (59.8 kDa), giving rise to a second band above that of hu c-Src in the c-833 
Src(wt) and c-Src(mt)-expressing cells. GAPDH runs at 36 kDa. qRT-PCR data shows mean + SD of 834 
two independent measurements. (D) Density plot showing logFC values of statistically 835 
significant (q ≤ 0.05) DE genes of mock, c-Src(wt) and c-Src(mt) cells compared with naïve MCF-836 
10A, obtained from RNA sequencing. (E) Correlation between RNA sequencing data and qRT-837 
40 
 
PCR measurements of 13 statistically significantly DE genes of the comparison c-Src(mt) vs. 838 
mock cells (Additional file 1: Figure S5). 839 
 840 
Figure 2 Functional analysis of c-Src(mt) effector genes. (A) Gene Ontology (GO) enrichment 841 
analysis. Displayed are the ten level 4 GO terms in the indicated categories with the lowest q 842 
values (see Additional file 2 for a complete list and corresponding gene lists). (B) Pathway 843 
analysis. Displayed are the twenty pathways with the lowest q values. Redundant pathways 844 
have been removed. Color code indicates pathways associated with different cellular processes. 845 
The complete list of pathways can be found in Additional file 3. (C) Selected genes and their 846 
relative expression levels in c-Src(mt) and c-Src(wt)-expressing cells with respect to mock cells. 847 
logFC values (q ≤ 0.05) are indicated by color code. Non-significant (q > 0.05) gene expression is 848 
shown in grey.   849 
 850 
Figure 3 c-Src(mt)-expressing cells exhibit elevated invasive potential in vivo. (A) SCID mice 851 
were injected i.v. with one of the four different cell lines and sacrificed 42 days later for 852 
histological analyses of their lungs. (B) Determination of lung metastases in mice injected with 853 
c-Src(mt)-expressing cells as visualized by H&E (Hematoxylin & Eosin) staining shown in C. (C) 854 
Macroscopic analysis of lungs. The arrow indicates a representative metastasis found in a 855 
mouse injected with c-Src(mt)-expressing cells. (D) Immunohistological stainings of lung tissues. 856 
Ki67, proliferating cells; Cl. Casp 3, apoptotic cells; F4/80, macrophages; Ly6G, granulocytes; 857 
CD3, T cells; B220, B cells. Scale bars, 50 µm.  858 
 859 
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Figure 4 Gene Ontology overrepresentation analysis of c-Src(mt) effector genes not linked to 860 
migration. For details, refer to Additional file 4. 861 
  862 
Figure 5 ONCOMINE analysis of c-Src(mt) effector genes. (A) q values of gene expression 863 
overlaps with cancer vs. normal tissue pairs (left) and with metastatic vs. localized cancer pairs 864 
(left) are shown. A complete list of primary cancer samples and gene lists can be found in 865 
Additional file 5. (B) Non-migration-associated c-Src(mt) effector genes with significant 866 
deregulation in cancer vs. normal tissue pairs are shown. 867 





